blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2411519

EP2411519 - KANAMYCIN ANTISENSE NUCLEIC ACID FOR THE TREATMENT OF CANCER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  27.05.2016
Database last updated on 31.08.2024
Most recent event   Tooltip17.08.2018Lapse of the patent in a contracting state
New state(s): BG		published on 19.09.2018  [2018/38]
Applicant(s)For all designated states
Chomienne, Christine
1 rue Gustave Mathieu
77590 Bois le Roi / FR
For all designated states
Padua, Rose Ann
18 Avenue Claude Vellefaux
75010 Paris / FR
[2015/37]
Former [2015/30]For all designated states
Institut National de la Santé et de la Recherche Médicale
101, rue de Tolbiac
75013 Paris / FR
For all designated states
Université Paris Diderot - Paris 7
5, rue Thomas Mann
75205 Paris Cedex 13 / FR
Former [2012/05]For all designated states
Institut National de la Santé et de la Recherche Medicale
101, rue de Tolbiac
75013 Paris / FR
For all designated states
Université Paris Diderot - Paris 7
5, rue Thomas Mann
75205 Paris Cedex 13 / FR
Inventor(s)01 / see applicant
...
 [2015/37]
Former [2012/05]01 / PADUA, Rose Ann
Unité de Biologie Cellulaire - Hôpital Saint Louis
- UMR-S-940 -
Institut Universitaire d'Hématologie
1 avenue Claude Vellefaux
F-75010 Paris / FR
02 / CHOMIENNE, Christine
Unité de Biologie Cellulaire - Hôpital Saint Louis
- UMR-S-940 -
Institut Universitaire d'Hématologie
1 avenue Claude Vellefaux
F-75010 Paris / FR
Representative(s)Domenego, Bertrand
Cabinet Lavoix
2, Place d'Estienne d'Orves
75441 Paris Cedex 09 / FR
[N/P]
Former [2015/30]Domenego, Bertrand
Cabinet Lavoix
2, place d'Estienne d'Orves
75441 Paris Cedex 09 / FR
Former [2012/05]Domenego, Bertrand
Cabinet Lavoix 2, place d'Estienne d'Orves
75441 Paris Cedex 09 / FR
Application number, filing date10711388.826.03.2010
WO2010EP54039
Priority number, dateEP2009029022427.03.2009         Original published format: EP 09290224
[2012/05]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2010109016
Date:30.09.2010
Language:EN
[2010/39]
Type: A1 Application with search report 
No.:EP2411519
Date:01.02.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 30.09.2010 takes the place of the publication of the European patent application.
[2012/05]
Type: B1 Patent specification 
No.:EP2411519
Date:22.07.2015
Language:EN
[2015/30]
Search report(s)International search report - published on:EP30.09.2010
ClassificationIPC:C12N15/113, A61K31/7088, A61K39/39
[2015/04]
CPC:
C12N15/1137 (EP,US); A61K39/39 (EP,US); A61P31/04 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61K2039/53 (EP,US);
C12N2310/11 (EP,US); C12N2310/111 (EP,US) (-)
Former IPC [2012/05]C12N15/113, A61K31/7088
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/05]
Extension statesALNot yet paid
BANot yet paid
MENot yet paid
RSNot yet paid
TitleGerman:KANAMYCIN-ANTISENSE-NUCLEINSÄURE ZUR BEHANDLUNG VON KREBS[2015/04]
English:KANAMYCIN ANTISENSE NUCLEIC ACID FOR THE TREATMENT OF CANCER[2012/05]
French:ACIDE NUCLÉIQUE ANTISENS DE LA KANAMYCINE POUR LE TRAITEMENT CONTRE LE CANCER[2015/11]
Former [2012/05]KANAMYCIN-ANTISENSE-NUKLEINSÄURE ZUR KREBSBEHANDLUNG
Former [2012/05]ACIDE NUCLÉIQUE ANTISENS DE RÉSISTANCE À LA KANAMYCINE POUR LE TRAITEMENT D'UN CANCER
Entry into regional phase19.10.2011National basic fee paid 
19.10.2011Designation fee(s) paid 
19.10.2011Examination fee paid 
Examination procedure19.10.2011Examination requested  [2012/05]
16.05.2012Amendment by applicant (claims and/or description)
09.11.2012Despatch of a communication from the examining division (Time limit: M06)
25.04.2013Reply to a communication from the examining division
15.11.2013Despatch of a communication from the examining division (Time limit: M04)
29.01.2014Reply to a communication from the examining division
05.09.2014Despatch of a communication from the examining division (Time limit: M04)
16.12.2014Reply to a communication from the examining division
12.02.2015Communication of intention to grant the patent
12.06.2015Fee for grant paid
12.06.2015Fee for publishing/printing paid
12.06.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  09.11.2012
Opposition(s)25.04.2016No opposition filed within time limit [2016/26]
Fees paidRenewal fee
21.03.2012Renewal fee patent year 03
21.03.2013Renewal fee patent year 04
19.09.2014Renewal fee patent year 05
30.03.2015Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
31.03.201405   M06   Fee paid on   19.09.2014
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU26.03.2010
AT22.07.2015
BE22.07.2015
BG22.07.2015
CY22.07.2015
CZ22.07.2015
DK22.07.2015
EE22.07.2015
FI22.07.2015
HR22.07.2015
LT22.07.2015
LV22.07.2015
MC22.07.2015
MK22.07.2015
PL22.07.2015
RO22.07.2015
SE22.07.2015
SI22.07.2015
SK22.07.2015
SM22.07.2015
TR22.07.2015
NO22.10.2015
GR23.10.2015
IS22.11.2015
PT23.11.2015
IE26.03.2016
LU26.03.2016
MT31.03.2016
[2018/38]
Former [2018/31]HU26.03.2010
AT22.07.2015
BE22.07.2015
CY22.07.2015
CZ22.07.2015
DK22.07.2015
EE22.07.2015
FI22.07.2015
HR22.07.2015
LT22.07.2015
LV22.07.2015
MC22.07.2015
MK22.07.2015
PL22.07.2015
RO22.07.2015
SE22.07.2015
SI22.07.2015
SK22.07.2015
SM22.07.2015
TR22.07.2015
NO22.10.2015
GR23.10.2015
IS22.11.2015
PT23.11.2015
IE26.03.2016
LU26.03.2016
MT31.03.2016
Former [2018/29]HU26.03.2010
AT22.07.2015
BE22.07.2015
CY22.07.2015
CZ22.07.2015
DK22.07.2015
EE22.07.2015
FI22.07.2015
HR22.07.2015
LT22.07.2015
LV22.07.2015
MC22.07.2015
MK22.07.2015
MT22.07.2015
PL22.07.2015
RO22.07.2015
SE22.07.2015
SI22.07.2015
SK22.07.2015
SM22.07.2015
TR22.07.2015
NO22.10.2015
GR23.10.2015
IS22.11.2015
PT23.11.2015
IE26.03.2016
LU26.03.2016
Former [2018/28]HU26.03.2010
AT22.07.2015
BE22.07.2015
CY22.07.2015
CZ22.07.2015
DK22.07.2015
EE22.07.2015
FI22.07.2015
HR22.07.2015
LT22.07.2015
LV22.07.2015
MC22.07.2015
MK22.07.2015
MT22.07.2015
PL22.07.2015
RO22.07.2015
SE22.07.2015
SI22.07.2015
SK22.07.2015
SM22.07.2015
NO22.10.2015
GR23.10.2015
IS22.11.2015
PT23.11.2015
IE26.03.2016
LU26.03.2016
Former [2017/47]AT22.07.2015
BE22.07.2015
CZ22.07.2015
DK22.07.2015
EE22.07.2015
FI22.07.2015
HR22.07.2015
LT22.07.2015
LV22.07.2015
MC22.07.2015
MT22.07.2015
PL22.07.2015
RO22.07.2015
SE22.07.2015
SI22.07.2015
SK22.07.2015
NO22.10.2015
GR23.10.2015
IS22.11.2015
PT23.11.2015
IE26.03.2016
LU26.03.2016
Former [2017/07]AT22.07.2015
BE22.07.2015
CZ22.07.2015
DK22.07.2015
EE22.07.2015
FI22.07.2015
HR22.07.2015
LT22.07.2015
LV22.07.2015
MC22.07.2015
PL22.07.2015
RO22.07.2015
SE22.07.2015
SI22.07.2015
SK22.07.2015
NO22.10.2015
GR23.10.2015
IS22.11.2015
PT23.11.2015
IE26.03.2016
LU26.03.2016
Former [2017/03]AT22.07.2015
BE22.07.2015
CZ22.07.2015
DK22.07.2015
EE22.07.2015
FI22.07.2015
HR22.07.2015
LT22.07.2015
LV22.07.2015
MC22.07.2015
PL22.07.2015
RO22.07.2015
SE22.07.2015
SI22.07.2015
SK22.07.2015
NO22.10.2015
GR23.10.2015
IS22.11.2015
PT23.11.2015
LU26.03.2016
Former [2016/49]AT22.07.2015
CZ22.07.2015
DK22.07.2015
EE22.07.2015
FI22.07.2015
HR22.07.2015
LT22.07.2015
LV22.07.2015
MC22.07.2015
PL22.07.2015
RO22.07.2015
SE22.07.2015
SI22.07.2015
SK22.07.2015
NO22.10.2015
GR23.10.2015
IS22.11.2015
PT23.11.2015
LU26.03.2016
BE31.03.2016
Former [2016/47]AT22.07.2015
CZ22.07.2015
DK22.07.2015
EE22.07.2015
FI22.07.2015
HR22.07.2015
LT22.07.2015
LV22.07.2015
PL22.07.2015
RO22.07.2015
SE22.07.2015
SI22.07.2015
SK22.07.2015
NO22.10.2015
GR23.10.2015
IS22.11.2015
PT23.11.2015
LU26.03.2016
BE31.03.2016
Former [2016/36]AT22.07.2015
CZ22.07.2015
DK22.07.2015
EE22.07.2015
FI22.07.2015
HR22.07.2015
LT22.07.2015
LV22.07.2015
PL22.07.2015
RO22.07.2015
SE22.07.2015
SI22.07.2015
SK22.07.2015
NO22.10.2015
GR23.10.2015
IS22.11.2015
PT23.11.2015
BE31.03.2016
Former [2016/23]AT22.07.2015
CZ22.07.2015
DK22.07.2015
EE22.07.2015
FI22.07.2015
HR22.07.2015
LT22.07.2015
LV22.07.2015
PL22.07.2015
RO22.07.2015
SE22.07.2015
SK22.07.2015
NO22.10.2015
GR23.10.2015
IS22.11.2015
PT23.11.2015
Former [2016/22]AT22.07.2015
CZ22.07.2015
DK22.07.2015
EE22.07.2015
FI22.07.2015
HR22.07.2015
LT22.07.2015
LV22.07.2015
PL22.07.2015
SE22.07.2015
NO22.10.2015
GR23.10.2015
IS22.11.2015
PT23.11.2015
Former [2016/20]AT22.07.2015
DK22.07.2015
FI22.07.2015
HR22.07.2015
LT22.07.2015
LV22.07.2015
PL22.07.2015
SE22.07.2015
NO22.10.2015
GR23.10.2015
IS22.11.2015
PT23.11.2015
Former [2016/11]AT22.07.2015
FI22.07.2015
HR22.07.2015
LT22.07.2015
LV22.07.2015
PL22.07.2015
SE22.07.2015
NO22.10.2015
GR23.10.2015
IS22.11.2015
PT23.11.2015
Former [2016/10]FI22.07.2015
HR22.07.2015
LT22.07.2015
LV22.07.2015
PL22.07.2015
SE22.07.2015
NO22.10.2015
GR23.10.2015
IS22.11.2015
PT23.11.2015
Former [2016/09]FI22.07.2015
LT22.07.2015
LV22.07.2015
NO22.10.2015
GR23.10.2015
Former [2016/08]LT22.07.2015
NO22.10.2015
Former [2016/07]LT22.07.2015
Cited inInternational search[A]WO03090778  (INST NAT SANTE RECH MED [FR], et al) [A] 1-15 * the whole document *;
 [A]  - PADUA ROSE ANN ET AL, "PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia.", NATURE MEDICINE NOV 2003, (200311), vol. 9, no. 11, ISSN 1078-8956, pages 1413 - 1417, XP002541189 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1038/nm949
 [A]  - MARIE ROBIN ET AL, "Targeted immunotherapy in acute myeloblastic leukemia: from animals to humans", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, (20051001), vol. 54, no. 10, ISSN 1432-0851, pages 933 - 943, XP019333072 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1007/s00262-005-0678-1
ExaminationEP1538206
 US2005260619
by applicantWO03090778
 WO9416737
 EP0187702
 WO9011092
 US5283185
 WO9115501
 WO9526356
 US5527928
 WO9318759
 WO9319768
 WO9425608
 WO9502397
 WO9100359
 WO9317706
 US4945050
 US5015580
 WO9424263
    - STEVENSON ET AL., IMMUNOLOGICAL REVIEWS, (1995), vol. 145, pages 211 - 28
    - SYRENGELAS ET AL., NATURE MEDICINE, (1996), vol. 2, pages 1038 - 41
    - RICE ET AL., NATURE REVIEWS, (2008), vol. 8, pages 108 - 20
    - PADUA ET AL., NATURE MEDICINE, (2003), vol. 9, pages 1413 - 1417
    - BROWN ET AL., PROC NATL ACAD SCI USA., (1997), vol. 94, pages 2551 - 6
    - PADUA; CHOMIENNE, DISCOVERY MEDICINE, (2004), vol. 4, pages 41 - 44
    - THE ET AL., NATURE, (1990), vol. 347, pages 558 - 61
    - DENGLER ET AL., ANTICANCER DRUGS, (1995), vol. 6, pages 522 - 32
    - GORCZYCA, CANCER RES., (1993), vol. 53, pages 1945 - 51
    - GRAHAM, B. S. ET AL., J. INFECT. DIS., (20061215), vol. 194, pages 1650 - 1660
    - MIR ET AL., PROC NATL ACAD SCI USA., (1999), vol. 96, pages 4262 - 7
    - OMIDVAR ET AL., CANCER RES, (2007), vol. 67, pages 11657 - 67
    - FURUGAKI ET AL., BLOOD, (2010), vol. 115, pages 653 - 6
    - FAN ET AL., NAT MED., (2009), vol. 15, pages 566 - 71
    - OMIDVAR ET AL., CANCER RES., (2007), vol. 67, pages 11657 - 67
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.